Moreover, widespread prostate-specific antigen (PSA) screening for the early detection of PCa has been linked to overdiagnosis and overtreatment, whereas no biomarker is available to discern between tumors that will remain indolent and those that will progress (2). The gene discussed is KLK3; the disease is posterior cortical atrophy.